Günter U Höglinger Selected Research

Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)

12/2021	[Neuroprotective treatment of tauopathies].
10/2021	Neuropathology of progressive supranuclear palsy after treatment with tilavonemab - Author's reply.
1/2021	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.
1/2021	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [ 18 F]PI-2620.
1/2021	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
1/2021	In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies.
1/2021	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
1/2021	iPS Cell-Based Model for MAPT Haplotype as a Risk Factor for Human Tauopathies Identifies No Major Differences in TAU Expression.
1/2021	DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy.
11/2020	Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Günter U Höglinger Research Topics

Disease

36	Parkinson Disease (Parkinson's Disease) 07/2022 - 09/2003
25	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 12/2021 - 11/2005
19	Tauopathies 12/2021 - 11/2005
16	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 11/2005
8	Parkinsonian Disorders (Parkinsonism) 01/2021 - 01/2004
7	Synucleinopathies 07/2022 - 07/2014
6	Corticobasal Degeneration 12/2021 - 01/2018
6	Disease Progression 01/2021 - 10/2013
5	Alzheimer Disease (Alzheimer's Disease) 12/2021 - 12/2011
5	Multiple System Atrophy 01/2019 - 01/2017
4	Atrophy 01/2022 - 04/2014
3	Movement Disorders (Movement Disorder) 08/2021 - 01/2020
3	Cerebellar Ataxia (Dysmetria) 01/2019 - 02/2016
2	Amyloidosis 10/2021 - 01/2021
2	Glioma (Gliomas) 05/2021 - 01/2014
2	Neuroinflammatory Diseases 01/2021 - 12/2020
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2019
2	Brain Diseases (Brain Disorder) 01/2020 - 12/2011
2	Schizophrenia (Dementia Praecox) 12/2011 - 06/2011
1	Confusion (Bewilderment) 01/2022
1	Panic Disorder (Panic Attack) 01/2022
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 12/2021
1	Pick Disease of the Brain (Pick's Disease) 12/2021
1	Nervous System Heredodegenerative Disorders 07/2021
1	Pantothenate Kinase-Associated Neurodegeneration (Hallervorden-Spatz Disease) 07/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2021
1	Tremor (Tremors) 01/2020
1	Migraine Disorders (Migraine) 01/2020
1	Myocardial Infarction 01/2020
1	Nervous System Diseases (Neurological Disorders) 01/2020
1	Essential Tremor (Essential Tremors) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Coronary Disease (Coronary Heart Disease) 01/2020
1	Prodromal Symptoms 01/2019
1	Gliosis 01/2019
1	Lewy Body Disease (Lewy Body Dementia) 01/2018

Drug/Important Bio-Agent (IBA)

11	Biomarkers (Surrogate Marker)IBA 10/2021 - 10/2013
8	alpha-SynucleinIBA 07/2022 - 11/2005
8	tau Proteins (tau Protein)IBA 12/2021 - 11/2005
8	SynucleinsIBA 01/2021 - 02/2016
7	Proteins (Proteins, Gene)FDA Link 10/2021 - 02/2016
6	annonacinIBA 01/2017 - 01/2004
5	Protein Isoforms (Isoforms)IBA 11/2021 - 12/2011
5	Levodopa (L Dopa)FDA LinkGeneric 12/2017 - 10/2013
4	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 12/2021 - 11/2016
4	tideglusibIBA 01/2017 - 04/2014
4	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 05/2015 - 01/2010
3	LigandsIBA 01/2021 - 07/2017
3	davunetideIBA 01/2017 - 07/2014
3	Oxidopamine (6 Hydroxydopamine)IBA 05/2015 - 03/2008
2	AntibodiesIBA 07/2022 - 01/2021
2	Glucosylceramidase (Glucocerebrosidase)IBA 01/2022 - 09/2015
2	Glucose (Dextrose)FDA LinkGeneric 10/2021 - 01/2021
2	tilavonemabIBA 10/2021 - 01/2021
2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2021
2	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2021
2	PesticidesIBA 01/2020 - 11/2018
2	Dopamine (Intropin)FDA LinkGeneric 07/2017 - 07/2004
2	Phosphotransferases (Kinase)IBA 01/2017 - 08/2015
2	NeurotoxinsIBA 01/2017 - 01/2008
2	Dopamine Agonists (Dopamine Agonist)IBA 09/2015 - 10/2013
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2015 - 12/2012
2	Glycogen Synthase (Synthase I)IBA 04/2014 - 04/2014
2	Neuregulin-1 (Neuregulin 1)IBA 12/2012 - 06/2011
2	neuromelaninIBA 02/2011 - 01/2007
2	AcetogeninsIBA 07/2007 - 01/2004
1	Glucosylceramides (Glucocerebrosides)IBA 01/2022
1	Cholinergic Agents (Cholinergics)IBA 01/2022
1	GlycosphingolipidsIBA 01/2022
1	venglustatIBA 01/2022
1	Biological ProductsIBA 01/2022
1	Amyloid beta-PeptidesIBA 12/2021
1	Neuroprotective AgentsIBA 10/2021
1	IronIBA 07/2021
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2021
1	gosuranemabIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Biocompatible Materials (Biomaterials)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	ParaffinIBA 01/2021
1	Prescription DrugsIBA 01/2021
1	Protein AggregatesIBA 01/2021
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2020
1	Albuterol (Salbutamol)FDA LinkGeneric 01/2020
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2020
1	Propranolol (Inderal)FDA LinkGeneric 01/2020
1	SmokeIBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	THK5351IBA 01/2019
1	Nicotine FDA Link 01/2019
1	Monoamine Oxidase (MAO)IBA 01/2019
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2019
1	Mannitol (Osmitrol)FDA LinkGeneric 01/2019
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2019

Therapy/Procedure

12	Therapeutics 05/2021 - 10/2007
2	Activities of Daily Living (ADL) 02/2021 - 01/2020
2	Drug Therapy (Chemotherapy) 01/2019 - 01/2019
1	Aftercare (After-Treatment) 10/2021
1	Immunotherapy 08/2021
1	Polypharmacy 12/2017